AI-Designed Vaccine Enters Human Trials, but the Real Test Is Just Beginning
A UK team has applied artificial intelligence to antigen selection for a Crimean-Congo hemorrhagic fever vaccine, opening a new path for a high-risk disease that has long lacked vaccine tools. But from an algorithmic hit to protection in humans, there remains a long distance involving safety, immune responses, and clinical validation.